Exone end to end binder jetting service

More Efficient Drug Screening with 3D Bioprinting

INTAMSYS industrial 3d printing

Share this Article

Taking a drug to market is a competitive, costly and challenging process involving preclinical laboratory and animal testing before the even more time-consuming and expensive four phases of human clinical trials, which can take as many as 7 to 15 years at price tags as high as $5.5 billion. Even if 10 viable drug compounds are identified for human trials, only 1 out of 9 will actually make it to market. Given this high attrition rate, can bioprinting save valuable time and resources by better identifying viable compounds in order to move only the most promising drugs to clinical trials?

The limitations of animal testing

During the initial stages of drug discovery, often referred to as preclinical trials, new chemical entities (NCEs) are monitored to determine the life cycle of the compounds inside and outside of the targeted system (pharmacokinetics) and their chemical reactions (metabolism). Because of the ethical issues surrounding human trials and their high costs, a significant number of these early tests are performed on animals.

While the transition from preclinical animal testing to clinical human trials has improved thanks to better research tools and the rise of artificial intelligence in target identification, there is still a real need for improved preclinical screening because animal testing often fails to recapitulate the complexity of the human metabolism, leading to false positives and negatives that do not accurately reflect the toxicity of drugs to human systems.

3D cell cultures are more relevant

Given the limitations of animal models, it is no wonder that scientists have turned to human organ models. But although human cells have long been cultured in 2D, in recent years, a paradigm shift has led more and more scientists to recognize the importance of working with human cells in the 3D environments afforded by bioprinting in order to produce more physiologically relevant models. Combining the automation of cell culturing in 3D bioprinting with carefully tailored biomaterials, known as bioinks, has made it possible to grow, feed and maintain human organ models in larger quantities and in a lot less time, reducing time and labor spent on these tasks. Laboratory robotics can also now pick and place cell culture reagents or other NCEs and liquid samples in high numbers, enabling higher throughput screening and running a variety of other laboratory tasks more efficiently.

Bioinks better mimic ECM

Bioinks are another powerful tool that help researchers advance their drug discovery research. Tissue-specific bioinks improve cell adhesion and differentiation, helping with the formation of human organoids. Proteins and other biological factors can also be added to more accurately recreate extracellular matrices (ECM), once again better simulating the in vivo microenvironments. Furthermore, with multiple methods of crosslinking (chemical, light, thermal), the stiffness of constructs can be modulated to better serve specific cell types, like cartilage or bone tissue.

Learn more

Bioprinting’s more relevant human organ models can save the drug industry time and money by more efficiently identifying viable compounds in the initial stages of drug development in order to move only the most promising compounds to costly human clinical trials. The technology’s growing influence means that scientists continue to validate more and more applications. Dive deeper into how the bioprinting industry is changing drug screening and development. Watch our webinar on 3D bioprinting for COVID-19 studies or read our application note, which discusses the effectiveness of testing drug efficacy in 2D and 3D.

Share this Article


Recent News

$51M to Ramp up 6K’s Production of Batteries and 3D Printing Metals

Secret Audit Reveals US Military’s 3D Printing Tech Vulnerable to Cyberattacks



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Printing News Briefs, September 9, 2021: Events, Materials, & More

In today’s 3D Printing News Briefs, the first Formnext + PM South China finally opens this week. In materials news, a biomedical company introduced what it calls the first purified...

Featured

US Navy Issues $20M to Stratasys to Purchase Large-Format 3D Printers

The U.S. Navy has been steadily increasing its investment into practical 3D printer usage, as opposed to research. The latest comes in the form of a whopping $20 million contract...

3D Printing Webinar and Event Roundup: August 22, 2021

From food 3D printing and GE Additive’s Arcam EBM Spectra L 3D printer to 3D printing and CAD in a post-pandemic world and topology optimization, we’ve got a busy week...

Featured

The Largest 3D Printed Structure in North America: a Military Barracks in Texas

ICON’s latest 3D printed training barracks structure in Texas signals another positive step for the additive construction industry. Described by the company as the largest 3D printed structure in North...


Shop

View our broad assortment of in house and third party products.